Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2022 annual meeting of stockholders (the "Annual Meeting") of Agile Therapeutics, Inc. (the "Company") held on June 9, 2022, the following proposals were submitted to the stockholders of the Company:

Proposal 1:The election of three directors to serve as Class II directors until the Company's 2025 annual meeting of stockholders and until their successors are duly elected and qualified.

Proposal 2:Approval, on a non-binding advisory basis, of the 2021 compensation of our named executive officers.

Proposal 3:Approval of an amendment to Agile Therapeutics, Inc.'s Amended and Restated 2014 Incentive Compensation Plan.

Proposal 4:The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.

For more information about the foregoing proposals, see the proxy statement filed by the Company with the Securities and Exchange Commission on April 29, 2022. Of the 146,741,862 shares of the Company's common stock entitled to vote at the Annual Meeting, 78,982,445, or approximately 53.82% were represented at the meeting virtually in person or by proxy, constituting a quorum. The number of votes cast for, against, or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below:

Proposal 1:Election of Directors.

The Company's stockholders elected the following three directors to serve as Class II directors until the Company's 2025 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows:

Director


                            Votes For  Votes Withheld  Broker Non-Votes

Sandra Carson, M.D. FACOG 34,958,134 7,153,217 36,871,094



Seth H.Z. Fischer         34,653,126     7,458,225        36,871,094

Josephine Torrente        31,557,528     10,553,823       36,871,094

Proposal 2:Advisory Non-Binding Vote on 2021 Executive Compensation.

The Company's stockholders approved, on a non-binding advisory basis, the 2021 compensation of our named executive officers. The votes regarding this proposal were as follows:

Votes For Votes Against Votes Abstaining Broker Non-Votes

35,598,524 6,189,341 323,486 36,871,094

Proposal 3: Approval of an amendment to Agile Therapeutics, Inc.'s Amended and


             Restated 2014 Incentive Compensation Plan

Votes For Votes Against Votes Abstaining Broker Non-Votes

35,745,234 5,966,010 400,107 36,871,094

The Company's stockholders approved an amendment to the Company's Amended and Restated 2014 Incentive Compensation Plan. The votes regarding this proposal were as follows:

Proposal 4: Ratification of Appointment of Ernst & Young LLP.

The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The votes regarding this proposal were as follows:

Votes For Votes Against Votes Abstaining



 75,213,682      3,277,982           490,781

© Edgar Online, source Glimpses